Slingshot members are tracking this event:
Top line data from PROMISE 2, a Phase 3 study of Eptinezumab in 1,500 Chronic Migraine patients
Do you think this event is important to the companies below? How will it affect their stock price?
~ Earnings call 4q 2016
Slingshot Insights Explained
Feb 26, 2018
Related Keywords Eptinezumab, Promise 2, Chronic Migraine